THE VALUE OF C-REACTIVE PROTEIN MEASUREMENT IN RHEUMATOID-ARTHRITIS

被引:115
作者
OTTERNESS, IG
机构
关键词
CRP; DISEASE MANAGEMENT; THERAPY; RA;
D O I
10.1016/S0049-0172(05)80003-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since 1973, assessment of serum concentrations of C-reactive protein (CRP) has been advocated as a objective measure of disease activity in rheumatoid arthritis (RA). Our review of clinical experience with CRP measurement suggests it has at least two important roles to play in the management of RA. First, persistently elevated CRP levels have prognostic value. In general, such elevated levels are found in those patients who are at greater risk for continuing joint deterioration and therefore may need more aggressive treatment and supportive care. Second, in general, improvement in CRP levels is an objective indication that a drug has produced a beneficial effect and thus may be useful to the physician for monitoring effects of therapy. Since CRP may be elevated in a number of conditions besides RA, a diagnosis of RA must be made before using CRP as a prognostic factor. Copyright (C) 1994 by W.B. Saunders Company
引用
收藏
页码:91 / 104
页数:14
相关论文
共 128 条
  • [1] D-PENICILLAMINE WITHDRAWAL IN RHEUMATOID-ARTHRITIS
    AHERN, MJ
    HALL, ND
    CASE, K
    MADDISON, PJ
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1984, 43 (02) : 213 - 217
  • [2] RHEUMATOID-ARTHRITIS - RELATION OF SERUM C-REACTIVE PROTEIN AND ERYTHROCYTE SEDIMENTATION-RATES TO RADIOGRAPHIC CHANGES
    AMOS, RS
    CONSTABLE, TJ
    CROCKSON, RA
    CROCKSON, AP
    MCCONKEY, B
    [J]. BRITISH MEDICAL JOURNAL, 1977, 1 (6055) : 195 - 197
  • [3] RHEUMATOID-ARTHRITIS - C-REACTIVE PROTEIN AND ERYTHROCYTE SEDIMENTATION-RATE DURING INITIAL TREATMENT
    AMOS, RS
    CROCKSON, RA
    CROCKSON, AP
    WALSH, L
    MCCONKEY, B
    [J]. BRITISH MEDICAL JOURNAL, 1978, 1 (6124) : 1396 - 1396
  • [4] ANDERSON IF, 1983, S AFR MED J, V63, P923
  • [5] [Anonymous], 1959, ANN RHEUM DIS, V18, P173
  • [6] ASTBURY C, 1992, BRIT J RHEUMATOL, V31, P461
  • [7] Aylward M, 1975, Rheumatol Rehabil, V14, P101, DOI 10.1093/rheumatology/14.2.101
  • [8] AYLWARD M, 1980, ROYAL SOC MED, V28, P101
  • [9] BALLOU SP, 1992, ADV INTERNAL MED, V37, P313
  • [10] BALTZ ML, 1985, CLIN EXP IMMUNOL, V59, P243